Immunic Appoints Jason Tardio as Chief Operating Officer and President

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company focused on small molecule therapies for chronic inflammatory and autoimmune diseases, has announced the appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024. Mr. Tardio, a former executive at Novartis and Biogen, brings extensive experience in the commercialization of multiple sclerosis drugs to his new role at Immunic.

Jason Tardio will lead efforts to prepare for the potential launch of vidofludimus calcium (IMU-838), an orally available nuclear receptor related 1 (Nurr1) activator. He will collaborate with Patrick Walsh, Chief Business Officer, to explore potential partnerships for this and other drug candidates.

Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, emphasized the importance of Tardio’s appointment, highlighting the strategic timing as the company nears the completion of its phase 3 ENSURE program for vidofludimus calcium and awaits the results of its phase 2 CALLIPER trial in April 2025. Immunic also announced the promotion of Werner Gladdines to Chief Development Officer, underscoring its focus on advancing clinical operations.

Jason Tardio expressed his enthusiasm about joining Immunic and contributing to the development of new treatment options for relapsing and progressive forms of multiple sclerosis. His extensive background includes key roles in launching MS drugs such as MAYZENT® and AVONEX® PEN.